​

Biohaven Stock (NYSE:BHVN)

ForecastRevenueOwnershipFinancialsChart
Biohaven by TradingView

Previous Close

$14.01

52W Range

$12.79 - $55.70

50D Avg

$14.61

200D Avg

$25.39

Market Cap

$1.49B

Avg Vol (3M)

$1.99M

Beta

3.50

Div Yield

-

BHVN Company Profile

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

256

IPO Date

Sep 23, 2022

Website

BHVN Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceJun 22Mar 22
Product$193.95M$123.59M
Collaboration And Other-$195.26M

Fiscal year ends in Dec 24 | Currency in USD

BHVN Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-885.11M$-436.05M$-567.93M
Net Income$-846.42M$-408.17M$-570.28M
EBITDA$-885.11M$-429.14M$-462.80M
Basic EPS$-9.28$-5.73$-12.75
Diluted EPS$-9.28$-5.73$-12.75

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 21Feb 25, 22 | 8:30 AM
Q3 21Nov 09, 21 | 1:08 PM
Q2 21Aug 09, 21 | 8:30 AM

Peer Comparison

TickerCompany
AMLXAmylyx Pharmaceuticals, Inc.
PRTGPortage Biotech Inc.
APLSApellis Pharmaceuticals, Inc.
DNLIDenali Therapeutics Inc.
BBIOBridgeBio Pharma, Inc.
BPMCBlueprint Medicines Corporation
ARVNArvinas, Inc.